(Alliance News) - Tuesday's dead cat bounce didn't live past the morning in Europe, with the FTSE 100 back in the red at midday as investors fret over an upcoming US interest rate decision. Read More
(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning and Monday: Read More
(Alliance News) - Average pay in the UK is failing to keep up with rampant inflation, though the country's jobless rate remains at nearly a 50-year low, posing a conundrum for the Bank of England when it meets this week. Read More
(Alliance News) - Daiichi Sankyo Co Ltd on Monday said it dosed the first patient in the Tropion-Breast02 phase three trial, evaluating the safety and efficacy of datopotamab deruxtecan in patients with breast cancer. Read More
(Alliance News) - AstraZeneca PLC on Thursday said Calquence, when used in combination with obinutuzumab, showed a longer-term survival rate in people with a form of leukaemia. Read More
(Alliance News) - AstraZeneca PLC on Wednesday said its Evusheld antibody reduces the risk of serious Covid-19 symptoms or death from the virus in vulnerable sufferers. Read More
(Alliance News) - Equities in London had a buoyant start to the week after a four-day break, with oil majors and miners leading the gainers amid optimism over easing Covid rules in China. Read More
(Alliance News) - Stock prices in London were higher at midday on Monday following the long holiday weekend in the UK, after an easing of virus lockdowns in China, while the pound appreciated ahead of a no-confidence vote in Westminster. Read More
(Alliance News) - AstraZeneca PLC on Saturday said its jointly developed breast cancer drug Enhertu showed improved overall survival in a phase III trial, while its leukaemia treatment Calquence showed a sustained survival benefit in another phase III trial. Read More
(Alliance News) - AstraZeneca PLC on Monday announced its Covid-19 vaccine Vaxzevria has received approval from the EU to be used as a third-dose booster jab. Read More
(Alliance News) - Kingfisher on Monday said first-quarter sales were above pre-pandemic levels but had weakened year-on-year. The owner of the B&Q chain of DIY stores also unveiled a GBP300 million share buyback. Read More
(Alliance News) - Kingfisher on Monday said first-quarter sales were above pre-pandemic levels but had weakened year-on-year. The owner of the B&Q chain of DIY stores also unveiled a GBP300 million share buyback. Read More
(Alliance News) - Europe's blue-chip stock benchmarks were drifting aimlessly at midday on Wednesday, as markets seemed unsure how to react to hot inflation figures in the UK and the eurozone. Read More
(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and Tuesday afternoon: Read More
(Alliance News) - AstraZeneca PLC on Tuesday said it signed a license agreement with RQ Biotechnology Ltd to develop, manufacture and sell Covid antibodies worldwide. Read More
(Alliance News) - AstraZeneca PLC on Sunday said its rescue medication candidate PTO27 showed positive results in its Mandala Phase III trial. Read More
(AllianceNews) - NetScientific PLC on Monday said its subsidiary ProAxsis Ltd had successfully completed the development and evaluation of an AstraZeneca PLC Covid-19 antibody test with "impressive" results. Read More
(Alliance News) - AstraZeneca PLC on Thursday reported several positive developments in its pipeline, including its breast cancer drug clearing another regulatory hurdle, and positive phase III trial results for Farxiga and Ultomiris. Read More
(Alliance News) - AstraZeneca PLC on Wednesday said its checkpoint inhibitor drug Imfinzi, generically durvalumab, has been granted priority review by the US Food & Drug Administration. Read More
(Alliance News) - JD Wetherspoon on Wednesday said sales improved steadily since the ending of all Covid restrictions, but the pub chain said virus woes have been replaced by "considerable pressure on costs" as a new source of concern. Read More